Latest Guard Therapeutics News & Updates

See the latest news and media coverage for Guard Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Guard Therapeutics

Clinical-stage biotech developing kidney disease therapies

guardtherapeutics.com
Headquarters
Stockholm, Sweden
Company type
Public company
Number of employees
2–15

Last updated

Latest news about Guard Therapeutics

In short: Guard Therapeutics evaluated strategic alternatives, including potential mergers or liquidation, after discontinuing its lead drug candidate.

Company announcements

  • Guard Therapeutics

    Guard Therapeutics announces Nasdaq observation status

    Nasdaq notes insufficient active operations, risking delisting by June 17, 2026. Company evaluates merger or reverse acquisition; may recommend delisting and liquidation if no deal.

  • Guard Therapeutics

    Guard Therapeutics updates strategic review

    Company identifies potential merger or reverse takeover counterparties and plans due diligence in Q2 2026. If no alternatives, delisting and liquidation may follow.

  • Guard Therapeutics

    Guard Therapeutics updates strategic review status

    The review, exploring mergers or RTOs, progresses as planned and nears completion in Q1 2026. Significant interest exists, but liquidation is possible if no deal materializes.

  • Guard Therapeutics

    Guard Therapeutics announces participation in EU consortium for Alport syndrome

    The ALP-RARE project accelerates therapies for rare kidney diseases. Guard evaluates GTX peptide in preclinical models and contributes regulatory expertise. The consortium includes European institutions.

Unlock all announcements with a

Media coverage

  • Dagens industri

    Reduced losses for Guard Therapeutics

    Guard Therapeutics reports a result of minus 6.4 million kronor (minus 34.2) for the first quarter of 2026. Liquid funds at the end of...

  • Life Science Sweden

    Guard Therapeutics risks delisting from Nasdaq

    The crisis-hit biotech company Guard Therapeutics risks being delisted from Nasdaq First North Growth Market.

  • Dagens industri

    Guard Therapeutics to evaluate parties for reverse takeover

    Close Danske bank: This is why the Riksbank must panic-raise rates now. Susanne Spector, chief economist at Danske bank, was interviewed in Börsmorgon. The research company Guard Therapeutics has completed the overall exploratory work...

  • The Business Journals

    How a Peninsula company is racing its chronic kidney disease drug to the front of the pack

    To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company looks to...

Unlock all articles with a

Never miss news about Guard Therapeutics

Track Guard Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Guard Therapeutics competitors & trending companies

Browse news for competitors to Guard Therapeutics and other trending companies.